Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Filing Date: November 12, 2004
Reporting Period: The filing references financial results for the three months ended September 30, 2004, as detailed in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes or comparative financial data are disclosed within the body of this specific 8-K text. The document solely announces the issuance of the press release regarding the third-quarter results.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the press release is furnished under Item 2.02 but explicitly states it shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings.
Risks and Contingencies: No specific risks, contingencies, or unusual items are described in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 12, 2004) for actual financial figures, as they are not included in the 8-K text.
- Verify the specific revenue and net loss figures for the quarter ended September 30, 2004, in the attached press release.
- Confirm the company's cash position and burn rate from the full financial statements referenced in the press release.
- Check for any forward-looking statements or guidance included in the press release that may not be incorporated by reference in this 8-K.